PPT-Patent Litigation Overview

Intellectual Property Litigation for the NonLitigator June 2013 Table of Contents 1 Overview . ABA Section of Litigation 2012 Insurance Coverage Litigation Committee CLE Seminar, March 1-3, 2012: Please Excuse the Delay: The Consequences of Untimely Notice, Slow Investigation, and the Failure Intellectual Property Litigation for the Non-Litigator. June 2013. Table of Contents. 1. Overview ..................................................................................................................... Steven Steger. September 4, 2014. Reasons for Change. Combatting Patent Licensing Companies. NPEs, PAEs, Patent Trolls. Abusive Litigation Tactics. Supreme Court Scrutiny/Tension with Federal Circuit. VALUES . DECLINING. ?. GREY . GOLD . ADVISORS, LLC Wild Dunes 2015. Is the US ANTI PATENT?. Hard to Stop . Infringers. Damages Decline. Patent Litigation is Expensive. Patent Win Rates are Low. PTO Invalidates Contested Patents. . Effective Strategies for Avoiding and Interacting with them from the Perspective of In-House Counsel . 11:00 am – 12:15 pm. Speakers. James M. Francis. Fowler Bell PLLC. 300 West Vine Street, Suite 600. Monday June 13, 2016. Alice. – Impact on Patent Infringement Litigation Strategy. Overall Strategy Tip. For Plaintiff Patent-holders:. Make a thorough assessment of patent vulnerability to . Alice . for . AIPLA Corporate Practice Committee. Susan Kirsch, Partner. October 2015 . A Comparison of the UK, German, and French Patent Courts. United Kingdom. The European Courts - UK court structure. Court of Appeal. Antonio . Ferachi. – . Director, . Litigation Division . – LDR. Matthew A. Mantle – Partner – Jones Walker . LLP. LDR and LSBA . Tax Section – . Annual Liaison. . Meeting. Novem. ber 3. rd. September 26, 2013. Preliminary Case Assessment. Assess the factual allegations. Identify key witnesses. Locate key documents. Conduct preliminary witness interviews. Assess the legal allegations. Procedural: jurisdiction, venue, statute of limitations. . The Hepatitis C Treatment Revolution . Expanding Access to HIV Co-Infected and Beyond. UNITAID, MSF, WHO . IAC, Melbourne 21 July, 2014. Drugs of Interest - Hepatitis C.  . Sofosbuvir. Will likely be backbone of HCV all-oral pan-genotypic regimens. Agenda. Key Regulatory Exclusivities for Biologics. Additional Regulatory Exclusivities. Patent Strategy for Biologics. Comparison Between the 262(k) Pathway and the ANDA Pathway. Comparison Between the 262(k) Pathway and the ANDA Pathway (continued). 400 S. 7th Street | Suite 300 Las Vegas, NV 89101 Bruno van Pottelsberghe de la Potterie The Quality Factor in Patent Systems Vienna PATSTAT Conference 2010 Seite 2 von 5 II CRITERIA OF PATENT QUALITY - DPMA APPROACH 5 In order to gain a clearer und Are you looking to automate and manage your legal department or law firm? Then, MatterSuite is the best lawsuit management solution that caters to your needs and assists you in all aspects of your lawsuit, including litigation management, matter management, discovery, reporting, contact management, permission groups, calendaring, and much more. Make your legal department more efficient with an enterprise legal management (ELM) solution that supports multiple locations and languages.

For more details visit: https://www.mattersuite.com/litigation-management-software/